Results 1 to 10 of about 29,719 (208)
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge [PDF]
, 2017 Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem.
Alicia Ponte-Sucre +8 more
core +39 more sources
LEISHMANIA DONOVANI IN THE PERIPHERAL BLOOD [PDF]
Journal of Experimental Medicine, 1923 1. The effect of human red cells and serum on the growth of Leishmania donovani has been studied and a blood culture method devised, based on these findings. 2. The distribution of blood platelets and of the different varieties of leucocytes in the strata of centrifugalized diluted blood has been investigated, and also the distribution ...
Helen M. Van Sant, Charles W. Young
openaire +4 more sources
Homologous minicircles in Leishmania donovani [PDF]
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002 Leishmania minicircular deoxyribonucleic acid (DNA) is arranged into different classes according to sequence. These classes differ substantially in sequence, despite species- and genus-specific regions, and are present in widely different copy numbers within and between Leishmania strains.
Lambson, B., Barker, D.C.
openaire +3 more sources
Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against Leishmania donovani [PDF]
, 2020 A chemically diverse range of novel tetraoxanes was synthesized and evaluated in vitro against intramacrophage amastigote forms of Leishmania donovani. All 15 tested tetraoxanes displayed activity, with IC50 values ranging from 2 to 45 µm.
Amado, Patrícia +5 more
core +1 more source
Vaccine Development Against Leishmania donovani [PDF]
Frontiers in Immunology, 2012 La leishmaniasis visceral (VL) causada por Leishmania donovani y Leishmania infantum/chagasi representa la segunda enfermedad infecciosa más difícil en todo el mundo, lo que lleva a casi 500.000 nuevos casos y 60.000 muertes al año. La VL zoonótica causada por L.
Amrita Das, Nahid Ali
openaire +4 more sources
Proteomic analysis of the secretome of Leishmania donovani [PDF]
Genome Biology, 2008 Abstract Background Leishmania and other intracellular pathogens have evolved strategies that support invasion and persistence within host target cells. In some cases the underlying mechanisms involve the export of virulence factors into the host cell cytosol.
J Maxwell Silverman +12 more
openaire +4 more sources
In Vitro Screening Test Using Leishmania Promastigotes Stably Expressing mCherry Protein [PDF]
, 2014 Transgenic Leishmania major and Leishmania donovani axenic promastigotes constitutively expressing mCherry were used for in vitro antileishmanial drug screening. This method requires minimal sample manipulation and can be easily adapted to automatic drug
Miguel A. Morales, Vacchina, Paola
core +2 more sources
Evaluation of antigens for the serodiagnosis of kala-azar and oriental sores by means of the indirect immunofluorescence antibody test (IFAT) [PDF]
, 1981 Antigens and corresponding sera were collected from travellers with leishmaniasis returning to Germany from different endemic areas of the old world. The antigenicity of these Leishmania strains, which were maintained in Syrian hamsters, was compared by ...
A. Zuckermann +19 more
core +1 more source
The metabolism of Leishmania donovani in culture [PDF]
Biochemical Journal, 1954 Lei8hnmnia donovani, the organism causing visceral leishmaniasis, is a small, round or ovoid body measuring 2-5 g. in diameter, which occurs exclusively within cells of the reticulo-endothelial system of its mammalian host. In culture, or in the insect vector, the parasite exists in a flagellate leptomonad form. In the case of L. tropica in culture, it
J. D. Fulton, L. P. Joyner, S. Crowther
openaire +3 more sources
Structures, targets and recent approaches in anti-leishmanial drug discovery and development. [PDF]
, 2011 Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002.
Seifert, Karin
core +2 more sources